Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

Cusatis, George, Gregorc, Vanesa, Li, Jing, Spreafico, Anna, Ingersoll, Roxann G., Verweij, Jaap, Ludovini, Vienna, Villa, Eugenio, Hidalgo, Manuel, Sparreboom, Alex, Baker, Sharyn D.·2006·JNCI: Journal of the National Cancer Institute

Abstract

Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with activity in non-small-cell lung cancer. Diarrhea and skin toxicity are prominent gefitinib-related adverse events that potentially limit its use. Gefitinib is a substrate for ABCG2 (ABCP, BCRP, MXR), a polymorphic efflux transporter protein that is highly expressed in the intestines and liver. Here we investigated associations between allelic variants of EGFR, ABCG2, and the transporter protein ABCB1 with diarrhea and skin toxicity in gefitinib-treated patients. One variant, a common functional single-nucleotide polymorphism (SNP) in the ABCG2 gene, was associated with diarrhea in 124 patients treated with oral gefitinib 250 mg once daily; seven (44%) of 16 patients heterozygous for ABCG2 421C>A (Q141K) developed diarrhea, versus only 13 (12%) of 108 patients homozygous for the wild-type sequence (P = .0046). However, this SNP was not associated with skin toxicity (P = .99). The finding suggests that patients with reduced ABCG2 activity due to a common genetic variant are at increased risk for substrate drug-induced diarrhea, with implications for optimizing treatment with such agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djj469

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 241

Metadata

Authors
Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R. G., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M., Sparreboom, A., & Baker, S. D.
Venue
JNCI: Journal of the National Cancer Institute
Published
2006-12-06
Volume
98
Issue
23
Pages
1739-1742
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2147930289
Cited by
241
References
1
FWCI
14.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. https://app.cochat.ai/papers/10.1093/jnci/djj469
The paper
Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R. G., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M., Sparreboom, A., & Baker, S. D. (2006). Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djj469

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.